Keywords
Immunotherapy
Immune Checkpoint Inhibitors
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To evaluate effectiveness and survival of affected patients by melanoma via combined immunotherapeutic protocols. Methods: This is a scientific literature integrated review, which guiding question was: Is there any combined Immunotherapy protocol more efficient and with better survival rate to treat patients with melanoma? The bibliographic research was carried out through the following databases: US National Library of Medicine (PubMed) and Biblioteca Virtual em Saúde (BVS). The articles were loaded and analyzed in the Rayyan platform in order to identify and measure duplicated articles observing inclusion criteria. Results: Improved rates of overall survival, progression-free survival, and responses were observed with the new therapeutic protocols in immunotherapy, although toxicity and associated adverse effects were the main reasons for treatment discontinuation. Final considerations: The use of new therapeutic protocols with checkpoint inhibitors is highly promising, proving to be effective and enhancing survival for specific melanoma patients groups. However, further studies are needed to achieve a better risk-benefit parameter.
References
AMARIA RN, et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature, 2022; 611: 155-160.
ASCIERTO PA, et al. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial. Journal of Clinical Oncology, 2021; 41(2): 212-221.
COEN O, et al. The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC Cancer, 2021; 21(761): 1-10.
DA SILVA IP, et al. Site-Specific Response Patterns, Pseudoprogression, and Acquired Resistance in Patients With Melanoma Treated With Ipilimumab Combined With Anti–PD-1 Therapy. Cancer, 2020; 126(1): 86-97.
DIAB A, et al. Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001. Journal of Clinical Oncology, 2023; 41(30): 4756-4767.
EGGERMONT AMM, et al. PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. Future Oncology, 2022; 18(8): 903-913.
FERRUCCI PF, et al. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumabe, dabrafenib, and trametinib in BRAF-mutant melanoma. Journal for ImmunoTherapy of Cancer, 2020; 8(2): 1-9.
GROSSMAN KF, et al. Adjuvant pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma. American Association for Cancer Research Journals, 2022; 12(3): 644-653.
HAMID O, et al. Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. European Journal of Cancer, 2021; 157: 391-402.
HASANOV M, et al. An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma. OncoImmunology, 2021; 10(1): 1-10.
HUSSEIN AT, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. The NEW ENGLAND JOURNAL of MEDICINE, 2022; 386(1): 24-34.
KHATTAK MA, et al. Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study. European Journal of Cancer, 2022; 176(112957): 207-217.
LARKIN J, et al. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. European Journal of Cancer, 2022; 173: 285-296.
LARKIN J, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The NEW ENGLAND JOURNAL of MEDICINE, 2019; 381(16): 1535-1546.
LODDE GC, et al. Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study. European Journal of Cancer, 2023; 191(112957): 1-10.
LONG GV, et al. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma. NEJM Evidence, 2023; 2(4): 1-10.
LUKE JJ, et al. pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. The Lancet, 2022; 399(10336): 1718-1729.
OLSON DJ, et al. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. Journal of Clinical Oncology, 2021; 39(24): 2467- 2655.
SCHADENDORF D, et al. Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). European Journal of Cancer, 2019; 121: 144-153.
WOLCHOK JD, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2024; 40(2): 127-137.